At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to move toward success – both at the level of individual companies and for indications as a whole.
What one analyst called an “intriguing” overall survival signal in phase III results has Karyopharm Therapeutics Inc. planning to meet with the U.S. FDA about a would-be sNDA filing for Xpovio (selinexor) in myelofibrosis (MF).
Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized coumarin compounds targeting mitogen-activated protein kinase kinase reported to be useful for the treatment of cancer.
The Council of Scientific and Industrial Research has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Scientists from Nanyang Biologics Pte. Ltd. and Nanyang Technological University have divulged molephantinin derivatives reported to be useful for the treatment of colorectal cancer.
Overt Bio Inc. is advancing lead asset OVT-101 toward the clinic. The allogeneic, potential first-in-class, off-the-shelf γδ CAR T therapy targets claudin-6, which is present in the majority of ovarian cancers and several other solid tumors.
Glyconex Inc. has entered into a collaboration agreement with Nippon Kayaku Co. Ltd. to advance GNX201-ADC, a next-generation glycan-directed antibody-drug conjugate (ADC) candidate for the treatment of solid tumors.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has announced IND approval by China’s National Medical Products Administration (NMPA) for SKB-103 for the treatment of advanced solid tumors.
With incidence of kidney cancer rising in the U.K., the National Institute for Health and Care Excellence (NICE) published its first comprehensive guidelines for diagnosing and treating the disease.
RSS
